Clinical Trial

Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases

Study acronym: COLIBRI-GI
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to evaluate the superiority of ivonescimab combined with FOLFIRI over FOLFIRI + bevacizumab as second-line treatment of non resectable pMMR/MSS BRAFwt mCRC patients without liver metastases in terms of PFS. The main questions it aims to answer are: Does FOLFIRI + ivonescimab improve progression-free survival compared to FOLFIRI + bevacizumab? Participants will: Take FOLFIRI + ivonescimab or FOLFIRI + bevacizumab every 2 weeks for a maximum of 24 months Visit the clinic once every 2 weeks for checkups and tests, and have imaging done every 8 weeks Complete some quality of life questionnaires every 8 weeks
Protocol Amendment History 2 changes
notable Primary completion pushed: 2028-03 -> 2029-08 2026-05-20
minor Completion pushed: 2032-03 -> 2033-08 2026-05-20
Trial Details
NCT Number NCT07359456
Lead Sponsor UNICANCER
Collaborators: Summit Therapeutics
Conditions Metastatic Colorectal Cancer
Enrollment 130 participants
Start Date 2026-08-31
Primary Completion 2029-08 (estimated)
Study Completion 2033-08 (estimated)
Updated on ClinicalTrials.gov 2026-05-19